This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers
by Zacks Equity Research
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
Amgen's (AMGN) KRAS Inhibitor Gets CHMP Nod for Lung Cancer
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Amgen's (AMGN) KRAS inhibitor, Lumykras for the treatment of advanced non-small-cell lung cancer.
Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing
by Zacks Equity Research
Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC. Shares rise in after-market trading.
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of 45.99% and 91.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Mirati (MRTX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lilly's (LLY) Erbitux Gets FDA Nod for Expanded Use in CRC
by Zacks Equity Research
Eli Lilly (LLY) secures FDA approval for Erbitux combined with Pfizer's Braftovi to treat BRAF V600E mutation-positive metastatic CRC in adult patients who received prior therapy.
Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer
by Zacks Equity Research
Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
by Zacks Equity Research
Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.
Mirati (MRTX) Stock Dips on Wider-Than-Expected Q2 Loss
by Zacks Equity Research
Mirati's (MRTX) shares decline after the company's announcement of wider-than-expected loss per share for second-quarter 2021.
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
by Zacks Equity Research
Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.
Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer
by Zacks Equity Research
FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.
Moving Average Crossover Alert: Mirati Therapeutics (MRTX)
by Zacks Equity Research
Mirati Therapeutics (MRTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Mirati (MRTX) Down 15.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
by Zacks Equity Research
The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer
by Zacks Equity Research
The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.
Why Is Mirati (MRTX) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of 3.92% and 1580.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Mirati Therapeutics (MRTX) Might Surprise This Earnings Season
by Zacks Equity Research
Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mirati (MRTX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirati (MRTX) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirati (MRTX) Up 4.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mirati (MRTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.